- Home
- ANIX vs GNTA Comparison
ANIX vs GNTA Comparison
Compare ANIX & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | GNTA |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.3M | 34.0M |
| IPO Year | 1987 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANIX | GNTA |
|---|---|---|
| Price | $3.11 | $1.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 454.8K | 91.5K |
| Earning Date | 01-09-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.07 | $1.28 |
| 52 Week High | $5.46 | $10.00 |
Technical Indicators
Market Signals| Indicator | ANIX | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 36.50 |
| Support Level | $3.23 | $1.28 |
| Resistance Level | $3.44 | $1.59 |
| Average True Range (ATR) | 0.35 | 0.18 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 0.52 | 30.63 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.